Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LeMaitre VascularLMAT +0.78%100 6-1 Month Momentum % is 18.65% as of Aug. 07, 2026. GuruFocus rates LMAT with a GF Score™ of 100/100 and a GF Value™ of $95.26 (Modestly Undervalued). Among 843 Medical Devices & Instruments companies, LeMaitre Vascular ranks better than 85.29% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-07), LeMaitre Vascular's 6-1 Month Momentum % is 18.65%.
The industry rank for LeMaitre Vascular's 6-1 Month Momentum % or its related term are showing as below:
LMAT's 6-1 Month Momentum % is ranked better than 85.29% of 843
companies
in the Medical Devices & Instruments industry
Industry Median: -10.91
vs LMAT: 18.65
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
LeMaitre Vascular 6-1 Month Momentum % Related Terms
LMAT vs PLSE, XRAY, ATRC: 6-1 Month Momentum % Comparison
For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LeMaitre Vascular 6-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where LeMaitre Vascular's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LeMaitre Vascular (LMAT) has a 6-1 Month Momentum % of 18.65% as of Aug. 07, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on LeMaitre Vascular and its competitors. According to the industry distribution chart, LeMaitre Vascular ranks #124 out of 843 companies in the Medical Devices & Instruments industry, placing it in the top 14.7%.
Is LeMaitre Vascular's 6-1 Month Momentum % too high?
LeMaitre Vascular's current 6-1 Month Momentum % is 18.65%. Based on the distribution chart, LeMaitre Vascular ranks #124 out of 843 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, LeMaitre Vascular has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's 6-1 Month Momentum % compare to PLSE and XRAY?
According to the Medical Devices & Instruments industry distribution chart, LeMaitre Vascular ranks #124 out of 843 companies for 6-1 Month Momentum %. This places LeMaitre Vascular in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Medical Devices & Instruments company?
A good 6-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on LeMaitre Vascular and its competitors. LeMaitre Vascular's current 6-1 Month Momentum % is 18.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.26, compared to a current price of $81.45 — trading 14.5% below its estimated fair value. The current 6-1 Month Momentum % is 18.65%. LeMaitre Vascular's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current 6-1 Month Momentum % is 18.65% as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LeMaitre Vascular (LMAT) Overvalued in 2026?
Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued.
The current stock price of $81.45 is trading 14.5% below its estimated GF Value™ of $95.26.
GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.
Key valuation signals for LMAT:
6-1 Month Momentum %: 18.65%
GF Value™: $95.26 vs. price of $81.45 (14.5% below fair value)
No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
100GF Score
Get the complete analysis for LMAT
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMAT has been successfully added to your 
